News
In a paper published in MedComm, an international team of scientists provided an overview of the advancements in the ...
GT-02287 oral presentation demonstrates new evidence of disease-modifying capacity in GBA1 and idiopathic Parkinson's disease ...
Synthego and Vita Therapeutics Announce Strategic Licensing Agreement for hfCas12Max CRISPR Nuclease
This nonexclusive sublicense grants Vita Therapeutics access to the engineered hfCas12Max nuclease and optimized hfCas12Max guide RNAs for use in preclinical and clinical applications, including in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback